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OBJECTIVES We sought to investigate the effects of physical training on circulating proinflammatory
cytokines and the soluble apoptosis mediators Fas (sFas) and Fas ligand (sFasL) in patients
with chronic heart failure (CHF).
BACKGROUND Recent investigations have shown an overexpression of circulating proinflammatory cytokines
and soluble apoptosis mediators in patients with CHF, which may be related to their exercise
intolerance and clinical deterioration.
METHODS Plasma levels of tumor necrosis factor-alpha (TNF-alpha), soluble TNF receptors I and II
(sTNF-RI and sTNF-RII, respectively), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-
6R), sFas and sFasL were measured in 24 patients with stable CHF (New York Heart
Association functional class II/III; left ventricular ejection fraction 23.2  1.3%) and in 20
normal control subjects before and after a 12-week program of physical training in a
randomized, crossover design. Functional status of patients with CHF was evaluated by using
a cardiorespiratory exercise test to measure peak oxygen consumption (VO2max).
RESULTS Physical training produced a significant reduction in plasma levels of TNF-alpha (7.5 
1.0 pg/ml vs. 4.6  0.7 pg/ml, p  0.001), sTNF-RI (3.3  0.2 ng/ml vs. 2.7  0.2 ng/ml,
p  0.005), sTNF-RII (2.6  0.2 ng/ml vs. 2.3  0.2 ng/ml, p  0.06), IL-6 (8.3 
1.2 pg/ml vs. 5.9  0.8 pg/ml, p  0.005), sIL-6R (34.0  3.0 ng/ml vs. 29.2  3.0 ng/ml,
p 0.01), sFas (5.5 0.7 ng/ml vs. 4.5 0.8 ng/ml, p 0.05) and sFasL (34.9 5.0 pg/ml
vs. 25.2 4.0 pg/ml, p 0.05), as well as a significant increase in VO2max (16.3 0.7 ml/kg
per min vs. 18.7  0.8 ml/kg per min, p  0.001). Good correlations were found between
a training-induced increase in VO2max and a training-induced reduction in levels of the
proinflammatory cytokine TNF-alpha (r  0.54, p  0.01) and the apoptosis inducer
sFasL (r  0.57, p  0.005) in patients with CHF. In contrast, no significant difference in
circulating cytokines and apoptotic markers was found with physical training in normal
subjects.
CONCLUSIONS Physical training reduces plasma levels of proinflammatory cytokines and the sFas/sFasL
system in patients with CHF. These immunomodulatory effects may be related to the
training-induced improvement in functional status of patients with CHF. (J Am Coll
Cardiol 2002;39:653–63) © 2002 by the American College of Cardiology
Recent investigations have shown an overexpression of
proinflammatory cytokines and soluble apoptosis mediators
in patients with chronic heart failure (CHF), which may be
related to the cardiac and endothelial dysfunction charac-
terizing this syndrome (1,2). Thus, an abnormal immuno-
logic response appears to be an important factor in the
development and progression of the syndrome of CHF (3).
Proinflammatory cytokines, such as tumor necrosis factor
(TNF)-alpha and interleukin-6 (IL-6), are capable of mod-
ulating cardiac and peripheral vascular functions by a variety
of mechanisms, including abnormal regulation of nitric
oxide synthase (NOS) expression, overproduction of oxygen
free radicals and induction of cardiac myocyte and endothe-
lial cell apoptosis (4,5). In addition, overexpression of the
inducible form of NOS (iNOS) in the skeletal muscle of
patients with CHF, possibly triggered by circulating proin-
flammatory cytokines, appears to be responsible for the
attenuation of muscle contractile capacity and/or skeletal
myocyte apoptosis, both associated with the severity of
exercise tolerance limitation and the degree of CHF (6–8).
It has also been reported that circulating apoptosis media-
tors, such as soluble Fas (sFas) and soluble Fas ligand
(sFasL), are elevated in patients with CHF and correlated
well with the severity of symptoms and prognosis of patients
with heart failure (2,9,10).
To the best of our knowledge, no in vivo data exist on the
effects of physical training on circulating proinflammatory
cytokines and their soluble receptors, as well as the soluble
apoptosis receptor sFas and the soluble apoptosis inducer
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sFasL, in patients with CHF. Therefore, we sought to
investigate whether a physical training program affects the
serum levels of the proinflammatory cytokines TNF-alpha
and IL-6 and their soluble receptors, soluble tumor necrosis
factor receptor type I (sTNF-RI), soluble tumor necrosis
factor receptor type II (sTNF-RII) and soluble
intrerleukin-6 receptor (sIL-6R), as well as the serum levels
of apoptotic mediators expressed by the sFas/sFasL system,
and whether these training-induced changes are associated
with exercise tolerance, expressed by peak oxygen consump-
tion (VO2max), in 24 patients with stable, moderate to
severe CHF.
METHODS
Study group. Twenty-four patients with moderate to se-
vere CHF (age 55  2 years; New York Heart Association
functional class II/III) gave informed, written consent and
were studied in our Cardiology Department, in compliance
with the approval of Ethics Committee. The mean left
ventricular ejection fraction of patients with CHF, esti-
mated by two-dimensional echocardiography, according to
the modified Simpson’s formula, was 23.2  1.3%. Inclu-
sion criteria were: stable CHF of at least three months’
duration; ischemic etiology (n  11, as evidenced by
documented myocardial infarction and/or coronary arte-
riography and coronary artery bypass graft surgery) and
idiopathic dilated cardiomyopathy (n  13); a limitation of
exercise by dyspnea or fatigue only and the ability to achieve
a respiratory exchange ratio for at least unity; and the
absence of Holter monitoring evidence of ventricular tachy-
cardias or other serious arrhythmias. Patients with infec-
tions, malignancies, collagen or other inflammatory dis-
eases, as well as patients taking anti-inflammatory or
immunosuppressive agents for the last two weeks, were
excluded from our study. The control subjects consisted of
20 age- and gender-matched volunteers without acute or
chronic illness or any symptoms related to the cardiovascular
system.
Patients and healthy control subjects underwent a 12-
week, home-based, bicycle exercise training program or
asked to avoid exercise (detraining) in a randomized, cross-
over design. The training program consisted of five days per
week, 30 min per day; patients and normal control subjects
were instructed to exercise at 50 rpm to keep their contin-
uously monitored heart rate in the range of 60% to 80% of
their previously determined maximal heart rate. Compliance
with the program was assessed as the percentage of expected
bicycle wheel revolutions achieved over the training period.
Cardiopulmonary exercise testing. At each visit, after
overnight fasting and before drug administration, the pa-
tients performed a cardiopulmonary exercise stress test to
evaluate their exercise capacity by measuring VO2max
(ml/kg per min). Exercise testing with respiratory gas
exchange measurements was performed by using the
Medgraphics CPX/MAX (Medical Graphics Corp., St.
Paul, Minnesota) measuring system, while patients exer-
cised on a treadmill according to the Dargie protocol (11).
Blood pressure was measured with a mercury sphygmoma-
nometer, and the electrocardiogram was continuously mon-
itored with a computer-assisted system (Marquette Elec-
tronics Inc., Milwaukee, Wisconsin). All patients quit the
test because of dyspnea or fatigue, and in all patients the gas
exchange anaerobic threshold and a respiratory exchange
ratio 1.0 were reached. Peak oxygen consumption during
exercise was reported as the mean value during the last
minute of exercise.
Laboratory measurements. Serum was obtained at base-
line, after training and after detraining by centrifugation of
vacutainer gel clotter tubes at 3,000 rpm for 10 min. All
serum samples were stored at 70°C until the time of
analysis, and samples were assayed in duplicate for TNF-
alpha, IL-6, sTNF-RI, sTNF-RII, sIL-6R, sFas and sFasL
concentrations, using commercially available enzyme-linked
immunosorbent assay (ELISA) kits. For most of them
(TNF-alpha, IL-6, sTNF-RI, sTNF-RII, sIL-6R and
sFas), we used the R&D Systems kit (Minneapolis, Min-
nesota), whereas for sFasL, the Diaclone kit (Besancon,
France) was used. All kits had the following sandwich
ELISA format: the microtiter plates were already precoated
with a murine monoclonal antibody against the human
proinflammatory cytokine being measured. Standards of the
analyte and plasma samples-in-duplicate were added, along
with another antibody against another epitope of the analyte
conjugated to horse radish peroxidase for TNF-alpha, IL-6,
sTNF-RI, sTNF-RII, sIL-6R and sFas measurements.
Also, standards of the analyte and plasma samples-
in-duplicate were added, along with another biotinylated
antibody against another epitope of the analyte for sFasL
measurement. The samples were incubated for 1.5 h for
TNF-alpha, IL-6, sTNF-RI, sTNF-RII, sIL-6R and sFas
and 2 h for sFasL at room temperature. In the case of sFasL
determination, streptavidin-horse radish peroxidase was
Abbreviations and Acronyms
ANOVA  analysis of variance
CHF  chronic heart failure
ELISA  enzyme-linked immunosorbent assay
IL-6  interleukin-6
iNOS  (inducible) nitric oxide synthase
NO  nitric oxide
sFas  soluble Fas
sFasL  soluble Fas ligand
sIL-6R  soluble intrerleukin-6 receptor
sTNF-RI  soluble tumor necrosis factor receptor
type I
sTNF-RII  soluble tumor necrosis factor receptor
type II
TNF  tumor necrosis factor
VO2max  peak oxygen consumption
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added for an extra 30 min, after the wells were washed.
Finally, for all of them, the chromogen tetra-methyl benzi-
dine was added and incubated for 30 min in the dark. After
addition of 2N H2SO4, the optical densities at 450 nm
(reference filter 620 nm) were read, and standard curves
were plotted in an Organon Technika 530 (Turnhout,
Belgium) microplate reader.
All tests were performed before daily medication had
been taken and were conducted by a blinded observer.
Table 1 summarizes the demographic data and clinical
characteristics, as well as the individual values of the various
proinflammatory cytokines and apoptotic mediators, of
patients with heart failure.
Statistical analysis. Statistical analysis was carried out
according to the recommendations of Hills and Armit-
age(12) for crossover trials. Comparisons of values of the
proinflammatory cytokines and apoptotic mediators, as well
as VO2max at baseline, after training and after detraining,
were done by using analysis of variance (ANOVA) for
repeated measures, followed by Scheffe´’s procedure for post
hoc comparisons of mean values. Simple regression analysis
was performed to describe the relationship between the
training-induced changes in circulating cytokines and apo-
ptotic factors and VO2max. A p value0.05 was accepted as
statistically significant. Results are expressed as the mean
value  SE.
RESULTS
We demonstrated that physical training induced a signifi-
cant reduction (p 0.005 by ANOVA) in proinflammatory
cytokines and apoptotic factors, as compared with the
detraining period, in the group of patients with CHF. Thus,
a significant decrease in serum concentrations of the circu-
lating cytokine TNF-alpha was observed with training
(7.5  1.0 pg/ml vs. 4.6  0.7 pg/ml, p  0.001) (Fig. 1),
as well as decreases in sTNF-RI (3.3  0.2 ng/ml vs. 2.7 
0.2 ng/ml, p  0.005) and sTNF-RII (2.6  0.2 ng/ml vs.
2.3 0.2 ng/ml, p 0.06) (Fig. 2), the circulating cytokine
IL-6 (8.3  1.2 pg/ml vs. 5.9  0.8 pg/ml, p  0.005) and
its soluble receptor sIL-6R (34.0  3.0 ng/ml vs. 29.2 
3.0 ng/ml, p  0.01) (Fig. 3) and the apoptotic mediators
sFas (5.5  0.7 ng/ml vs. 4.5  0.8 ng/ml, p  0.05) and
sFasL (34.9  5.0 pg/ml vs. 25.2  4.0 pg/ml, p  0.05)
(Fig. 4). Exercise performance, expressed by VO2max, im-
proved with the exercise training program (16.3 
0.7 ml/kg per min vs. 18.7 0.8 ml/kg per min, p 0.001).
Significant correlations were found between the training-
induced improvement in VO2max and the percent reduction
in serum levels of the proinflammatory cytokine TNF-alpha
(r  0.54, p  0.01) and the apoptosis mediator sFasL
(r  0.57, p  0.005), indicating that the attenuation of
proinflammatory cytokine activation and the downregula-
Table 1. Demographic Data and Clinical Characteristics, as Well as Individual Values of the Various Proinflammatory Cytokines and
Apoptotic Mediators at Baseline
Pt.
No.
Age
(yrs) Drugs EF (%)
VO2 max
(ml/kg
per min)
sFas
(ng/ml)
sFasL
(pg/ml)
TNF-alpha
(pg/ml)
sTNF-RI
(ng/ml)
sTNF-RII
(ng/ml)
IL-6
(pg/ml)
sIL-6R
(ng/ml)
1 65 D, ACE 27 13.8 3.57 33.4 6.39 5.2 2.185 3.95 26.2
2 61 D, ACE, Dig. 16 14.0 4.21 32.1 4.42 4.7 2.854 8.60 31.9
3 57 D, ACE, AA 30 15.8 6.88 42.9 4.11 5.3 2.236 4.90 47.6
4 50 D, ACE 35 15.4 3.98 67.8 0.55 5.4 3.354 9.90 37.0
5 68 D, ACE 21 12.4 16.24 56.0 7.67 4.9 4.823 13.60 31.0
6 59 D, ACE, Dig. 28 15.0 2.4 31.7 2.23 2.4 1.922 8.20 23.5
7 63 D, ACE 14 13.1 5.17 66.2 4.66 2.6 2.487 1.95 33.8
8 70 D, ACE 19 16.6 6.77 35.1 4.02 3.9 2.790 2.40 39.0
9 44 D, ACE 29 14.1 1.34 75.9 7.93 6.1 1.525 7.80 22.0
10 64 D, ACE, Dig. 20 12.2 2.08 9.5 11.64 4.23 3.174 4.50 34.3
11 60 D, ACE, AA 25 13.6 8.71 20.6 5.78 3.2 3.257 9.20 38.9
12 54 D, ACE 23 16.8 3.29 4.3 1.97 3.7 2.440 7.40 67.5
13 67 D, ACE, BB 18 11.2 4.90 3.6 10.03 2.78 2.322 8.40 26.2
14 47 D, ACE, Dig. 22 19.7 4.80 54.8 11.90 2.5 4.798 7.80 28.6
15 55 D, ACE 15 20.3 6.43 86.1 10.66 2.4 2.340 6.60 42.4
16 44 D, ACE, BB 17 18.3 7.96 79.8 9.42 2.3 4.469 10.4 49.2
17 62 D, ACE 28 11.7 2.87 11.2 3.61 2.9 1.981 3.1 21.7
18 65 D, ACE 25 20.4 7.51 44.8 12.36 2.65 2.033 16.4 37.2
19 57 D, ACE, Dig. 18 16.8 3.66 6.78 3.80 2.86 3.212 8.2 19.3
20 40 D, ACE, BB 23 23.7 4.25 4.78 6.34 1.92 1.790 8.6 ND
21 49 D, ACE 20 15.7 11.47 21.6 17.3 4.4 2.965 25.5 30.4
22 35 D, ACE, AA 17 13.2 5.45 13.7 10.48 3.35 2.686 3.3 51.2
23 30 D, ACE, BB 34 23.5 2.72 12.2 10.72 2.14 1.944 5.3 ND
24 59 D, ACE 32 22.6 10.98 25.31 10.22 2.22 2.538 7.7 41.1
Mean
 SE
55  2 23.2  1.3 16.2  0.8 5.7  0.7 35.0  5.0 7.4  0.8 3.5  0.2 2.7  0.2 8.1  1.0 35.5  3.0
AA  antiarrhythmics; ACE  angiotensin-converting enzyme inhibitors; BB  beta blockers; D  diuretics; Dig.  digoxin; EF  ejection fraction; IL-6  interleukin-6;
ND  nondetectable; sFas  soluble Fas; sFasL  soluble Fas ligand; sIL-6R  soluble interleukin-6 receptor; sTNR-RI and -RII  soluble TNF receptor types I and II;
TNF-alpha  tumor necrosis factor-alpha; VO2max  peak oxygen consumption.
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tion of the sFas/sFasL system may contribute to the
improvement in exercise capacity achieved with physical
training in patients with CHF (Fig. 5).
As with the detraining period, physical training pro-
duced a significant reduction (p  0.005 by ANOVA) in
proinflammatory cytokines and apoptotic factors, as com-
pared with baseline, although no difference was detected
between baseline and detraining values for exercise perfor-
mance (16.2  0.8 ml/kg per min vs. 16.3  0.7 ml/kg
per min for VO2max), the various proinflammatory cyto-
kines (7.4  0.8 pg/ml vs. 7.5  1.0 pg/ml for TNF-alpha;
3.5  0.2 ng/ml vs. 3.3  0.2 ng/ml for sTNF-RI; 2.7 
0.2 ng/ml vs. 2.6  0.2 ng/ml for sTNF-RII; 8.1 
1.0 pg/ml vs. 8.3  1.2 pg/ml for IL-6; 35.5  3.0 ng/ml
vs. 34.0  and 3.0 ng/ml for sIL-6R) (Figs. 1 to 3) or the
apoptotic factors (5.7  0.7 ng/ml vs. 5.5  0.7 ng/ml for
sFas; 35.0  5.0 pg/ml vs. 34.9  5.0 pg/ml for sFasL)
(Fig. 4).
No difference was detected in either baseline or training-
induced changes in circulating proinflammatory cytokines,
their soluble receptors and the sFas/sFasL system between
patients with ischemic and dilated cardiomyopathy (data
not shown).
Circulating proinflammatory cytokines and apoptotic
mediators were significantly higher (p  0.01) in pa-
tients with CHF, as compared with normal control
subjects at baseline (7.4  0.8 pg/ml vs. 3.6  0.2 pg/ml
for TNF-alpha; 3.5  0.2 ng/ml vs. 1.2  0.1 ng/ml for
sTNF-RI; 2.7  0.2 ng/ml vs. 1.6  0.1 ng/ml for
sTNF-RII; 8.1  1.0 pg/ml vs. 3.0  0.2 pg/ml for IL-6;
35.5  3.0 ng/ml vs. 6.0  0.3 ng/ml for sIL-6R; 5.7 
0.7 ng/ml vs. 2.5  0.2 ng/ml for sFas; and 35.0 
5.0 pg/ml vs. 13.5  1.0 pg/ml for sFasL). Despite the
considerable improvement in all these variables with phys-
ical training in patients with CHF, their values still remain
higher (p  0.01) than the baseline values of the control
subjects.
It is worth mentioning that physical training produced
no significant changes in the circulating proinflammatory
cytokines (3.7  0.3 pg/ml vs. 3.5  0.3 pg/ml for
TNF-alpha; and 2.9  0.2 pg/ml vs. 2.8  0.2 pg/ml
for IL-6), their soluble receptors (1.17  0.2 ng/ml vs.
1.14  0.2 ng/ml for sTNF-RI; 1.5  0.1 ng/ml vs. 1.4 
0.1 ng/ml for sTNF-RII; and 5.8  0.2 ng/ml vs. 5.7 
0.3 ng/ml for sIL-6R) and the apoptosis mediators
(2.4  0.2 ng/ml vs. 2.3  0.2 ng/ml for sFas; and 13.8 
2.0 pg/ml vs. 13.0  2.0 pg/ml for sFasL) in the control
group of normal subjects.
DISCUSSION
Proinflammatory cytokines (i.e., TNF-alpha, IL-1 and
IL-6) cause myocardial and endothelial dysfunction in
patients with CHF (13,14), either by increasing the pro-
duction of oxygen free radicals, which, in turn, alter the
production of nitric oxide (NO) in the cardiovascular system
or by triggering apoptosis in myocardial and endothelial
cells through oxidative stress (15–18). Interleukin-6 and
related cytokines have also been implicated in the develop-
ment of cardiac hypertrophy, through stimulation of their
common receptor gp130 expressed in cardiac myocytes
(19–21). Proinflammatory cytokine hyperactivation is also
Figure 1. Effects of physical training on proinflammatory cytokine tumor necrosis factor (TNF)-alpha. Note the reduction in TNF-alpha levels with
training in patients with chronic heart failure.
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associated with increased gene expression of iNOS in the
skeletal muscle of patients with CHF, leading to attenua-
tion of mitochondrial energy transfer (and, thus, attenuation
of skeletal muscle contractile performance) and/or skeletal
myocyte apoptosis (6,7). These deleterious, central and
peripheral effects may be important pathophysiologic events
Figure 2. Effects of physical training on soluble tumor necrosis factor receptor type I (sTNF-RI) (top) and soluble tumor necrosis factor receptor type II
(sTNF-RII) (bottom). Note the reduction in sTNF-RI and sTNF-RII levels with training in patients with chronic heart failure.
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associated with the impaired exercise capacity of patients
with heart failure (8,22,23).
It is known that programs of physical training, by causing
sustained, pulsatile increases in peripheral blood flow, affect
the release of prostaglandins in the skeletal muscle micro-
vasculature (24), induce the expression of NOS and cyto-
Figure 3. Effects of physical training on interleukin-6 (IL-6) (top) and soluble interleukin-6 receptor (sIL-6R) (bottom). Training produced a significant
reduction in IL-6 and sIL-6R levels in patients with chronic heart failure.
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solic superoxide dismutase (25), a free radical scavenger, and
enhance Ca influx in endothelial cells, which is necessary
for both NO and prostaglandin synthesis (26).
In this report, we have shown that an exercise training
program intervenes in the various stages of inflammatory
and apoptotic processes in patients with CHF, by reducing
Figure 4. Effects of physical training on the soluble apoptosis mediators soluble Fas (sFas) (top) and sFas ligand (bottom). Note the decrease in both
apoptotic variables with training in patients with chronic heart failure.
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not only the major proinflammatory cytokines TNF-alpha
and IL-6, which enhance the cytokine cascade and are
potent inducers of apoptosis (27), but also the soluble
receptors of TNF-alpha and IL-6, which are products of a
monocyte-myocyte/endothelial cell interaction and biologic
modulators of circulating cytokine actions (28); sFasL, a
Figure 5. Correlations between training-induced changes in peak oxygen consumption (VO2max) and reductions in tumor necrosis factor (TNF)-alpha
(top) and soluble Fas (sFas) ligand (bottom) levels in patients with chronic heart failure.
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newly discovered potent cytokine that is homologous to
TNF-alpha and induces apoptosis by binding to its mem-
brane receptor Fas through the activation of caspases (29);
and the soluble apoptotic receptor sFas, which represents an
important signal for the initiation of the apoptotic process
in the cardiovascular system and may have prognostic
importance in the syndrome of CHF (2,8).
Proinflammatory cytokines and physical training. En-
hanced immune activation, reflected in increased circulating
levels of various proinflammatory cytokines (i.e., TNF-
alpha, IL-1 and IL-6), has been recently recognized to play
a significant role in the pathophysiology of CHF (1,14).
Although the mechanism for increased elaboration of IL-6
is not known, TNF-alpha is sufficient to induce IL-6 gene
(by releasing the nuclear binding protein nuclear factor-B)
and protein expression in a variety of cell types, suggesting
that there may be a “cytokine cascade” in the setting of CHF
(30). Despite the growing interest in the contribution of
cytokine activation to the central (myocardial contractility
and remodeling) and peripheral (skeletal muscular and
endothelial function) pathophysiology of CHF, few reports
exist regarding the influence of traditional pharmacologic
and nonpharmacologic medications on cytokine levels in
human CHF. For example, in patients with severe CHF,
high-dose angiotensin-converting enzyme therapy is asso-
ciated with a significant decrease in IL-6 activity (31), and
in patients with dilated cardiomyopathy, a reduction in
levels of IL-6 has been proposed to be important for the
beneficial effect of amlodipine on mortality in the Prospec-
tive Randomized AmlodIpine Survival Evaluation heart
failure study (32). In addition, an important immunoregu-
latory role of beta-blockers in modifying the dysregulated
cytokine network has been recently reported in patients with
dilated cardiomyopathy (33). For the first time, to the best
of our knowledge, our study reports on the immunomodu-
latory role of physical training in patients with CHF, as
demonstrated with significant reductions in circulating lev-
els of major proinflammatory cytokines (TNF-alpha and
IL-6), all inducers of myocyte (both cardiac and skeletal)
and endothelial cell apoptosis, all actively involved in car-
diovascular maladaptive remodeling (34), all associated with
progression of the syndrome and all powerful, independent
predictors of new heart failure episodes, death or the need
for heart transplantation (28,35–37).
The extracellular domains of the TNF-alpha receptors
(soluble proteins TNF-RI and TNF-RII) provide more
complete information on TNF-alpha activation in patients
with CHF (28). Analysis of our data confirmed a parallel
reduction of cytokines and all of their soluble receptors with
training, except for sTNF-RII, which showed a nonsignif-
icant trend (p  0.06) toward reduced levels in trained
patients. This partially discordant training effect on TNF-
alpha and sTNF-RII might provide stronger evidence for a
less pro-apoptotic serum for endothelial cells of the vascu-
lature and for myocytes of the striated muscles. We believe,
however, that reduced sTNF receptor levels after physical
training reflect deactivation of the whole TNF system,
possibly indicating that trained patients with CHF no
longer “require” protection and, therefore, recruitment of
TNF-alpha receptors to counterbalance the TNF-induced
detrimental effects. Moreover, there is growing evidence
underlining the prognostic significance of the enhanced
levels of the sTNF receptors (especially sTNF-RII) in the
syndrome of CHF (28,37). Previous reports have shown
that the increase in circulating TNF-alpha in patients with
CHF was associated with a substantial decrease in myocar-
dial TNF-alpha receptors and an increase in sTNF-alpha
receptors (28,38). Physical training, therefore, by virtue of
its anti-inflammatory and anti-apoptotic effects, may atten-
uate myocyte and endothelial cell TNF-alpha expression.
Thus, we hypothesize that tissue TNF-alpha receptors may
be upregulated with training into the cardiovascular system,
offering an additional explanation of the training-induced
reduction in sTNF-alpha receptor levels.
The extracellular domain of the human IL-6 receptor can
be detected as the soluble form (sIL-6R) into the circulation
of patients with CHF. Although the clinical significance of
elevated sIL-6R in CHF remains uncertain, it has been
postulated that, similar to the TNF-alpha system, overacti-
vation mechanisms may be responsible for sIL-6R release
into the circulation of patients with CHF (39). A training-
induced decrease in sIL-6R levels, associated with a parallel
reduction in IL-6 levels, reflects a deactivation of the IL-6
system, another multifunctional cytokine that mediates both
the immune and inflammatory responses.
The Fas/FasL system and physical training. To the best
of our knowledge, we are the first to demonstrate that
exercise training induces a significant reduction in sFas and
sFasL, two major soluble signaling molecules implicated in
the pathophysiology of the apoptotic process in the cardio-
vascular system (2,9).
Circulating sFas levels are increased in patients with
dilated cardiomyopathy in proportion to the severity of
heart failure and may provide prognostic information inde-
pendent of left ventricular geometry (40). Serum concen-
trations of sFas are also elevated in patients with myocarditis
and correlated with the soluble interleukin-2 receptor, a
marker of T-cell activation (41).
The soluble form of the apoptosis inducer FasL (convert-
ed from membrane-bound FasL to a soluble form by a
metalloproteinase [42]) is increased in patients with ad-
vanced CHF and may not be derived only from circulating
T lymphocytes and natural killer cells; endothelial cells, as
well as the myocardium, should be considered as important
contributors of sFasL in human CHF (29,43).
The Fas/FasL system, therefore, may play a significant
role in the regulation of central and peripheral immune
responses in CHF. Physical training downregulates the
Fas/FasL system and resets homeostasis at a lower level.
The detrimental overfunction of the system, expressed
mainly with the FasL-induced tissue (endothelial cells and
myocytes) apoptosis, therefore, is attenuated.
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A protective role of the soluble form of the Fas molecule
from FasL-mediated apoptosis has been recently described;
therefore, one could argue that physical training facilitates
apoptosis by causing a reduction in the sFas concentration.
We have demonstrated, however, that training also causes a
significant reduction in a broad spectrum of immunologic
variables characterized as major inducers of apoptosis (e.g.,
TNF-alpha, IL-6, sFasL), re-establishing the balance of the
Fas/FasL system. Therefore, the training-induced decrease
in sFas levels simply reflects re-establishment of a more
optimal balance of the Fas/FasL system, as well as reversal
of the ongoing “immune activation” associated with CHF.
Immunologic responses and exercise tolerance. The
good correlation between training-induced changes in ex-
ercise capacity and the proinflammatory cytokine TNF-
alpha and the apoptotic inducer sFasL indicates that exer-
cise training may exert its beneficial effects, at least partially,
by suppressing the proinflammatory cytokine activation
characterizing the progress and clinical deterioration of
CHF.
We have recently shown that exercise training programs
reduce inflammatory markers (e.g., granuloctye macrophage
colony-stimulating factor, monocyte chemoattractant
protein-1, soluble intercellular adhesion molecule-1, soluble
vascular cell adhesion molecule-1) indicative of a
macrophage-endothelial cell adhesive interaction, and that
inflammatory process may underlie exercise intolerance
associated with CHF (44). Our study extends this initial
observation, not only by interpreting a possible epiphenom-
enon, but also by shedding light on the fundamental
mechanisms implicated in the pathogenesis of exercise
intolerance, a cardinal characteristic of the syndrome. Phys-
ical training, therefore, by virtue of its anti-inflammatory
and anti-apoptotic effects, seems to beneficially regulate
peripheral immune responses, resulting in improvement in
exercise capacity. Proinflammatory cytokines and apoptotic
inducers have been implicated in the pathogenesis, not only
of myocardial dysfunction and cardiomyocyte death, but
also of skeletal myopathy (through their skeletal myocyte
apoptotic properties) (7) and endothelial dysfunction
(through endothelial activation or damage) (45).
Clinical implications. These observations support the no-
tion that immunologic and inflammatory responses are
important pathophysiologic features in CHF, and physical
training may improve exercise performance by modifying
the inflammatory status and the subsequent apoptotic pro-
cess of patients with this syndrome, as well as by possibly
reversing inflammation-induced deleterious effects on the
cardiovascular system. Thus, our study provides new insight
into the pathophysiologic mechanisms underlying the ben-
eficial effects of physical training on symptoms and exercise
tolerance in the complex syndrome of CHF.
It is, therefore, tempting to hypothesize that modulation
of immunologic variables is emerging as a major therapeutic
goal in the treatment of patients with CHF, and that
physical training may represent an important immuno-
modulatory option that may possibly intervene in the
progression of the disease.
Conclusions. We found that physical training causes a
significant decrease in the circulating proinflammatory cy-
tokines TNF-alpha and IL-6 and their soluble receptors
(TNF-RI, TNF-RII and IL-6R), as well as in the soluble
apoptosis inducer FasL and the soluble apoptosis receptor
Fas, and that these beneficial effects may be related to the
training-induced improvement in functional status of pa-
tients with CHF, suggesting that persistent immune acti-
vation appears to be involved in the impaired exercise
capacity characterizing this syndrome.
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